San Francisco-based iRhythm launched its Zio monitor and Zio long-term continuous (LTCM) ambulatory ECG monitoring service in Austria, the Netherlands, Spain and Switzerland. The technology, along with the supporting Zeus AI algorithm, picked up CE mark at the start of the year.

Zio builds on the previous-generation Zio XT with long-term, continuous cardiac monitoring for up to 14 days. It provides an end-to-end experience for patients with potential arrhythmias and demonstrates 99% patient compliance. iRhythm launched the next-generation monitor in the U.S. in September.

“We believe the introduction of the Zio service in these countries will positively disrupt the monitoring paradigm to align clinical practice with evidence and improve outcomes,” said Mintu Turakhia, iRhythm chief medical and scientific officer and EVP, iroduct innovation.

More about the iRhythm Zio offering

As the company’s smallest, lightest and thinnest cardiac monitor, Zio aims to enhance the cardiac monitoring experience for patients. The company said its new service enhancements also benefit healthcare providers.

Zio’s improved form factor comes in 23% thinner, 62% lighter and 72% smaller than the previous generation. It weighs just 10 grams. The device features a breathable, patient-centric design, waterproof housing, and an increased adhesive area. The system also has a symptom button for easier patient interaction and no maintenance or battery changes are required.

iRhythm plans to begin shipping Zio in the new geographies in September, with widespread availability anticipated in 2025.

“Expanding access to our innovative Zio cardiac arrhythmia monitoring system and services for millions more people in Europe is an important milestone for iRhythm’s patient-first mission to positively impact people across the globe,” said Quentin Blackford, iRhythm president and CEO. “Our commitment extends to broadening our highly innovative digital healthcare solutions, while ensuring they are cost-effective and accessible worldwide.”